National Center of Oncology (Azerbaijan)

Olympus to Launch Development Support Project in Kenya for the Diagnosis of Gastrointestinal Diseases

Retrieved on: 
Thursday, July 20, 2023
National Center of Oncology (Azerbaijan), Gastrointestinal cancer, Gastroenterology, Hereditary diffuse gastric cancer, Public, Health technology, Policy, Cancer, Olympus, Ministry of Health, Labour and Welfare, Kyushu University, Endoscopy, Kenyatta National Hospital, Global Health, Ministry, ODA, Physician, Colorectal cancer, Extrapyramidal system, Disease, Ministry of Health (Kuwait), Knowledge, Mortality, Death, Notifiable disease, Diagnosis, Medtech, Medicine, Pharmaceutical industry, Nursing, Health

from Nairobi Gastroenterology Training Centre, Kenyatta National Hospital said, "There is an increase of cancer cases in Kenya.

Key Points: 
  • from Nairobi Gastroenterology Training Centre, Kenyatta National Hospital said, "There is an increase of cancer cases in Kenya.
  • In Kenya, the proportion of non-communicable diseases as a cause of death has been growing.
  • This will be a combination of on-site training, training in Japan, and online training.
  • Olympus will arrange training courses and the equipment necessary for the training.

Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology

Retrieved on: 
Tuesday, May 23, 2023
National Center of Oncology (Azerbaijan), Triple-negative breast cancer, CPI, NCT, Hematology, OX40L, Cancer, Research, Lung cancer, MAGE, Patient, Melanoma, Peptide, Immune system, NY-ESO-1, Neoplasm, Pembrolizumab, CD40L, Tumor microenvironment, Safety, Pharmaceutical industry, Vaccine, Medical imaging

No other oncolytic virus therapy delivers tumor targets in this simple but effective and adaptable way.

Key Points: 
  • No other oncolytic virus therapy delivers tumor targets in this simple but effective and adaptable way.
  • The first patient has been administered with PeptiCRAd-1 successfully, without any initial safety concerns and the Safety Data Committee has concluded that the study can continue enrolment.
  • This is a truly innovative immuno-therapy approach which has shown great promise in the pre-clinical setting.
  • We hope to be able to translate this to positive clinical outcomes for patients.”
    “FOR PATIENTS” section on valotx.com for more information!

Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment

Retrieved on: 
Thursday, May 18, 2023
Professional Services, Oncology, Health, Venture Capital, Pharmaceutical, Biotechnology, National Center of Oncology (Azerbaijan), Rat, University of Stuttgart, University, PDX, Cytolysin, Harvard University, Syngenic, Tumor microenvironment, Chemistry, Hospital, Laboratory, MD Anderson Cancer Center, FIH, ADC, Spacecraft, Fibroblast, Pharmaceutical industry, Oncomatryx

The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment.

Key Points: 
  • The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment.
  • It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment.
  • Oncomatryx's pioneering drug OMTX705, which incorporates the cytolysin toxic payload developed by Tube, is a first-in-class antibody-drug conjugate targeting cancer-associated fibroblasts.
  • Oncomatryx now owns the comprehensive portfolio of cytolysins synthesized by Tube and the cutting-edge technology developed in its laboratories.

DGAP-News: CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen

Retrieved on: 
Wednesday, June 8, 2022
National Center of Oncology (Azerbaijan), Leadership, Pharmacovigilance, Head, Board of directors, CVAC, Genentech, Trust, CEO, Merck Group, RNA, Roche, Senior, Nasdaq, University, Medical school, Growth, RNA transfection, CureVac, Technology, Infection, COVID-19, Supervisory board, Novartis, Global Medical Aid, MD, Cancer, Board, Medical Affairs Bureau, Merck, GSK, Degenerative disease, Protein, Management, Pharmaceutical industry

CureVac is pleased to welcome Myriam Mendila to this key role.

Key Points: 
  • CureVac is pleased to welcome Myriam Mendila to this key role.
  • Until then, Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer.
  • "We would like to sincerely thank Klaus for his leadership across several strategically decisive projects.
  • We thank him for his contributions to CureVac and wish him well for his next professional steps."

Doctors say now is not the time to put your health on hold

Retrieved on: 
Monday, December 20, 2021
Proton, Omicron, Gaps, Bladder cancer, Neck, Cancer, Radiation, Brain, National Center for Biotechnology Information, COVID-19, Breast, Freedom, Megasphaera, Oncology, National Center of Oncology (Azerbaijan), Head, Prostate, Lung, Risk, Patient, Veterans' affairs, Disease, Proton therapy, Sarcoma, Health, Procurement, Pharmaceutical industry, Medical imaging

But medical experts warn that delaying routine health screenings could have an adverse effect on your health.

Key Points: 
  • But medical experts warn that delaying routine health screenings could have an adverse effect on your health.
  • Oncologists have been observing significant gaps in cancer screenings since the pandemic began in early 2020.
  • A new nationwide study based on data from Veterans Affairs hospitals, which was released earlier this month, provides additional evidence.
  • Scheduling annual health screenings play an important role in detecting cancer in its earliest, most treatable stage.

NOXXON to Host Key Opinion Leader Webinar on NOX-A12 and Radiotherapy Combination: a Differentiated and Promising New Approach to Treating Brain Cancer

Retrieved on: 
Tuesday, November 16, 2021
Medical Supplies, Biotechnology, Other Health, Health, Radiology, Pharmaceutical, Oncology, Research, Hospitals, Science, Clinical Trials, Society, Safety, University, Brain, SNO, Cancer, Neoplasm, Pakistan Society of Neuro-Oncology, University Hospital Bonn, EST, Glioblastoma, Immune system, Terminology, Department, Teaching hospital, KOL, GBM, TME, Pembrolizumab, Radiation therapy, DKFZ, MGMT, Radiation, ESMO, Standard of care, Tumor microenvironment, GLORIA, Research, American Society for Radiation Oncology, German Cancer Research Center, University Hospital Heidelberg, NCT, Annual general meeting, Peaceful transition of power, CET, Merck Sharp & Dohme Federal Credit Union, National Center of Oncology (Azerbaijan), CXCL12, Communication, Pancreatic cancer, ASTRO, NOX-A12, Patient, Pharmaceutical industry, Medical imaging, Risk management, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY

Frank Giordano, M.D., is Director and Chair of the Department of Radiation Oncology at the University Hospital Bonn, Germany.

Key Points: 
  • Frank Giordano, M.D., is Director and Chair of the Department of Radiation Oncology at the University Hospital Bonn, Germany.
  • For many years, his research has focused on optimized radiation therapy of brain cancers to offer cancer patients personalized and even more effective treatment.
  • NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers.
  • The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments.

TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting

Retrieved on: 
Monday, October 18, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Neutron, TLS, Technology, Cancer, Breast, ASTRO, Treatment of lung cancer, Radiation, American Society for Radiation Oncology, Economics, Health, Radiation therapy, BNCT, Patient, Head, Society, Research, Sale, Neutron capture therapy of cancer, National Center of Oncology (Azerbaijan), Neoplasm, Partnership, Mayo Clinic, Pharmaceutical industry, Medical imaging, BNCT, TAE Life Sciences, BNCT, TAE LIFE SCIENCES

TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry-Expert Theater session focused on advancements in BNCT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 24-27, 2021.

Key Points: 
  • TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry-Expert Theater session focused on advancements in BNCT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 24-27, 2021.
  • They will discuss the clinical application and technical advancements in BNCT for the treatment of invasive, recurrent and difficult to treat cancers.
  • BNCT differs radically from other radiation therapy and shows promise in becoming the next-generation cancer treatment.
  • TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).

TILT Biotherapeutics Announces Data at ESMO on Its Oncolytic Immunotherapy Platform

Retrieved on: 
Friday, September 17, 2021
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, European Innovation Council, Urine, University, Merck & Co., Trial of the century, National Center of Oncology (Azerbaijan), Business Finland, Patient, TILT, ESMO, Potyvirus, Cytokine, Saliva, Clinical trial, European Society for Medical Oncology, Neoplasm, Congress, TILS, Therapy, Merck, University of Copenhagen, University of Helsinki, Tumor microenvironment, CAR, Interim, TNF, Tumor necrosis factor, Cancer, EIC, Pharmaceutical industry, Vaccine, Medical imaging

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that the company presented yesterday clinical study results at the annual congress of the European Society of Molecular Oncology (ESMO).

Key Points: 
  • TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that the company presented yesterday clinical study results at the annual congress of the European Society of Molecular Oncology (ESMO).
  • Interim data from six patients shows that TILT-123 monotherapy or a combination of TILT-123 and tumor-infiltrating lymphocytes (TILs) is deemed safe with the lowest two dose levels of TILT-123.
  • TILT Biotherapeutics CEO, Akseli Hemminki, a biotech entrepreneur and oncologist who has personally treated 300 patients with eleven different oncolytic viruses, said, The annual ESMO congress is one of the worlds most prestigious oncology events, and I am delighted we were able to present there about recent progress with our oncolytic immunotherapy platform.
  • TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells.